Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets. Our mission is to become the world leader in developing better and safer antibody-based oncology products addressing clear unmet pediatric and adult medical needs. With the right partnerships and collaborations, we envision changing the course of cancer care and its outcomes.
Unlock the market timeline & signal feed
6 signals in the last 90 days.
The order this company entered each market — oldest to newest
Telix Appoints David Gill as Director
Telix Appoints David Gill as Director
Sign up to see the full signal feed
How Y-mAbs Therapeutics, Inc.'s international expansion compares to its competitors
Y-mAbs Therapeutics, Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Y-mAbs Therapeutics, Inc.You | 6 | 6 | -100% | 6 | 22 |
Senior Director / Director, Medical (Oncology)
View postingCopenhagen, Capital Region of Denmark, Denmark · 11mo ago
Senior Manager / Associate Director, GMP Global QA
View postingHørsholm, Capital Region of Denmark, Denmark · 11mo ago
Finance Manager
View postingHørsholm, Capital Region of Denmark, Denmark · last yr.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Telix Pharmaceuticals appoints David Gill as Non-Executive Director effective May 11, 2026, with plans for him to become Chair. Gill brings 35+ years of life sciences experience.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Y-mAbs Therapeutics, Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
